Paper Details

  1. Home
  2. Paper Details

Cancer risk with topical calcineurin inhibitors, pimecrolimus and tacrolimus, for atopic dermatitis: a systematic review and meta-analysis.

Author: , CeccacciRenata, ChuAlexandro, ChuDerek K, DevasenapathyNiveditha, LevineMitchell, LinClement, MacDonaldMargaret, PyneLonnie, SchneiderLynda, SrivastavaArchita, SteenJeremy, WenAaron, WongMelanie

Systematic ReviewA review that systematically collects, evaluates, and integrates relevant research to answer a specific research question.
Controlled Clinical TrialA clinical trial that evaluates the effectiveness of a treatment by comparing a group that receives the intervention with a group that receives a placebo or standard treatment.
Meta-AnalysisA statistical technique that integrates the results of multiple studies to draw more general conclusions about a particular issue.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

This systematic review examined the risk of cancer in patients with atopic dermatitis exposed to topical calcineurin inhibitors (pimecrolimus or tacrolimus).
Paper Details　
Original Abstract of the Article :
Atopic dermatitis is a prevalent condition in children and can be effectively managed with medications such as topical calcineurin inhibitors (pimecrolimus or tacrolimus). A key unresolved safety concern is whether use of topical calcineurin inhibitors is associated with cancer. We systematically re...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1016/S2352-4642(22)00283-8

データ提供：米国国立医学図書館（NLM）

Exploring the Potential Cancer Risk of Topical Calcineurin Inhibitors

The field of dermatology constantly grapples with the challenge of finding safe and effective treatments for conditions like atopic dermatitis. This research dives into the safety concerns surrounding the use of topical calcineurin inhibitors, specifically pimecrolimus and tacrolimus, in patients with atopic dermatitis. Employing a systematic review and meta-analysis, the authors aimed to assess the potential cancer risk associated with these widely used medications. The study's findings provide valuable insights into the long-term safety profile of topical calcineurin inhibitors.

A Closer Look at the Results

The study concluded that there is no significant association between the use of topical calcineurin inhibitors and an increased risk of cancer. This finding is reassuring for patients and dermatologists alike. It provides evidence-based support for the continued use of these medications in the management of atopic dermatitis, a condition affecting millions worldwide.

Peace of Mind for Atopic Dermatitis Patients

This research offers a sigh of relief for those struggling with atopic dermatitis. It highlights the safety of these commonly prescribed treatments, allowing patients to focus on managing their condition without excessive worry about potential long-term risks. However, it is essential to remember that all medications have potential side effects. It is always crucial to consult with a healthcare professional about any concerns and to discuss individual risk factors.

Dr. Camel's Conclusion

This research, like a cool oasis in the scorching desert of dermatological concerns, provides much-needed reassurance for patients and physicians. The study sheds light on the safety of topical calcineurin inhibitors, offering a beacon of hope for those battling atopic dermatitis. While it's important to always be mindful of potential side effects, this research reinforces the effectiveness and safety of these treatments in the long run.

Date :
  1. Date Completed 2022-12-20
  2. Date Revised 2023-02-10
Further Info :

Pubmed ID

36370744

DOI: Digital Object Identifier

10.1016/S2352-4642(22)00283-8

Related Literature

Article Analysis
・Effects of pimecrolimus topical
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.